Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

Combining Trodelvy with Keytruda and pushing it into the frontline setting could “potentially double” the ADC’s market in ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in ...

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

The study enrolled patients with a PD-L1 combined positive score (CPS) of 10 or more, matching Keytruda's label in first-line ...

US biotech major Gilead Sciences (Nasdaq: GILD) today announced positive top-line results from the Phase III ...

April 21 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's (MRK.N), opens new tab immunotherapy ...

The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC ...

Gilead Sciences has shared positive top-line results from a late-stage study evaluating its antibody-drug conjugate (ADC) ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...